Company Profile

Wilson Wolf Manufacturing Corporation (AKA: Wilson Wolf Corporation)
Profile last edited on: 1/31/2018      CAGE: 47J39      UEI: L1HKPVNJ33J8

Business Identifier: Contract engineering for cellculture technology
Year Founded
1997
First Award
1999
Latest Award
2019
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

33 5th Avenue Nw Suite 700
Saint Paul, MN 55112
   (651) 628-9259
   info@wilsonwolf.com
   www.wilsonwolf.com
Location: Single
Congr. District: 04
County: Ramsey

Public Profile

Wilson Wolf Manufacturing Corporation provides contract engineering and manufacturing resources for medical device suppliers. The company develops products that advance the field of cell culture by creating devices that bridge the gap between traditional cultureware (t-flasks and roller bottles) and sophisticated devices like WAVE bioreactors and hollow fiber bioreactors. The firm’s efforts have led to highly beneficial devices that typically rely on the use of gas permeable material and/or dialysis membranes to provide a healthier environment for cells that utilizes less labor, less material, less space, and makes downstream processing much easier. The firm is currently developing its G-Rex technology platform for cell production in Adoptive Immunotherapy. Applications proven to be much more efficient in G-Rex Devices include: T Cell culture (research and clinical production of antigen-specific T cells, CAR T cells, EBV-CLT, TIL, NK, Treg, HSC, LCL, K562, etc.) Monoclonal and recombinant antibody production (hybridoma, CHO, 293, etc.) Islet culture (up to 4000 IE/cm2).

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 2 NIH $7,758,826
Project Title: Islet culture, shipping, and infusion device
2018 2 NIH $3,083,305
Project Title: Overcoming the Last Barrier to Commercialization of Virus-Specific T Cell Therapy
2014 2 NIH $1,171,608
Project Title: Moving Til Therapy Past the Valley of Death
2010 1 NIH $113,520
Project Title: Superior Cell Culture Device for More Efficient Biological Production
2006 1 NIH $122,649
Project Title: Highly efficient gas permeable cell culture devices

Key People / Management

  Mark Hirschel -- COO

  Daniel P Welch -- Director of Product Development

  John R Wilson -- Chief Executive Officer

  Martin L Wolf

Company News

There are no news available.